Compare Heron Therapeutics Inc (HRTX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Uranium Energy Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Uranium Energy Corp trades at $9.33 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 66.6× Heron Therapeutics Inc's market cap, and Uranium Energy Corp is more actively traded (10,888,578 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Uranium Energy Corp for 37 Days on average.
| HRTX | UEC | |
|---|---|---|
Market Cap | $68.01M | $4.53B |
Volume | 1,891,941 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $1.49 | $20.14 |
52-Week Low | $0.27 | $9.04 |
Typical Hold Time | 35 Days | 37 Days |
Enterprise Value | $174.75M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a net income margin of -368.62% and has missed earnings expectations in recent quarters. However, the company is expanding production capacity with two operational mines and benefits from growing U.S. government demand for domestic uranium.
While analyst consensus remains strongly bullish with an 87.5% buy rating and $16.06 price target, fundamental challenges persist including negative cash flow from operations and unproven production sustainability. The stock faces execution risks as it scales operations, but long-term uranium demand tailwinds provide potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
